Outset Medical (OM) Q1 2026 Earnings Transcript

Outset Medical reported Q1 revenue of $27.9 million, down 6% year over year, but expanded non-GAAP gross margin 620 bps to 43.8% and cut non-GAAP net loss 32% to $15.4 million. Management reaffirmed 2026 guidance for $125 million to $130 million in revenue and low- to mid-40% gross margin, while lowering expected 2026 cash usage to less than $40 million from prior expectations. The company also highlighted a next-generation Tableau launch with FDA cybersecurity-compliance as a potential second-half growth catalyst and said roughly 70% of revenue is now recurring.

Analysis

The setup is less about a near-term revenue beat and more about a potential inflection in revenue quality. With roughly 70% recurring mix already, the marginal dollar is becoming more valuable than the headline top line because it should carry higher visibility, better retention, and less working-capital drag than console-heavy growth. If management is right that next-gen refreshes pull forward replacements, the stock can re-rate on multiple expansion before absolute revenue acceleration is obvious.

The second-order winner is any peer selling into hospital cybersecurity budgets or EMR-adjacent workflows, because this company is effectively reframing dialysis equipment as a secure software-enabled infrastructure decision. That broadens the buying committee from nephrology to IT/security and procurement, which tends to elongate cycles but enlarge deal size and reduce competitor price leverage. The risk is that this same dynamic also invites more incumbent-style competition from integrated device players once the category is validated.

The biggest near-term tell is not the Q2 guide; it is whether the company converts pipeline into signed orders during the limited-release window for the new platform. If the launch resonates, the stock can work on “multiple-on-multiple” expansion even with modest revenue growth, because lower cash burn and improving gross margin reduce dilution fears. If deal timing slips again, however, the market will quickly revert to treating the platform as a long-duration story with financing overhang.

Contrarian view: the market may be underestimating how much of the thesis depends on execution discipline rather than product superiority. Cybersecurity differentiation is real, but healthcare buyers are notoriously slow to change vendors, so the launch needs a clean implementation narrative, not just a feature list. The upside asymmetry is best captured if the company proves it can convert older installed-base refreshes without re-creating the same lumpy capital cycle.

Key Decisions for Investors

• Initiate a small tactical long OM position ahead of the next launch window, sized for event-driven upside over the next 6-12 weeks; target is a re-rating if order conversion improves, but cap downside with a 5-7% stop because timing risk remains high.
• Prefer a pairs trade: long OM / short a higher-multiple medtech peer with less recurring revenue visibility over the next 1-2 quarters, betting that recurring mix and cash burn improvement get rewarded more than generic healthcare growth.
• Buy OM call spreads into the limited-release and full-launch period, using 2-4 month expiries; the payoff is asymmetric if management starts to prove that refresh demand is pulling forward without additional dilution.
• Avoid chasing strength in the first print after launch unless you see evidence of accelerated large-deal closes; this remains a timing-sensitive story and can fade quickly if Q2 is only a modest step-up.